Headlines about MeiraGTx (NASDAQ:MGTX) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative
Conventional wisdom suggests that investors should find safe stocks to buy. Penny stocks and potential “triple-baggers” might be more exciting and a big win might provide a better story, but experts will tell you the smart play is to benefit from compounding returns in safe, stable stocks.
That general strategy is similar to that followed by Warren Buffett with Berkshire Hathaway....More>>>
Media coverage about Accelerate Diagnostics (NASDAQ:AXDX) has been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accelerate Diagnostics....More>>>
&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-514451378&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/514451378/960×0.jpg?fit=scale&q; data-height=&q;639&q; data-width=&q;960&q;&g; Company logo of Apple on an Apple store in Manhattan on February 25, 2016 in New York, United States of America. (Photo by Thomas Trutschel/Photothek via Getty Images)
It would be fair to say biotech has had an interesting time of it over the course of the past 15 months. Except, of course, that biotech always has an interesting time of it. The go big or go home sector of the market attracts speculators, scientists, and unsavory characters, but also attracts people hoping for critical improvements to their healthcare options.
The casino sector offers a lot of color beyond the characters one expects to find as their customers according to the movies. Local nuances in Macau, Las Vegas, online gambling, and new areas lead to industry-wide changes and company-level opportunities for investors.
Recent headlines have focused on headwinds in Macau – with revenue down for its third consecutive year but perhaps bottoming....More>>>
No one likes paying any kind of taxes, so you might think that in any ranking of the most hated tax Americans have to pay, every tax you have to pay would all tie for first. That said, we’re in the middle of income tax season, and there’s been plenty of political and tax policy discussion about the negative impacts of the estate tax, which many call the death tax. Yet neither the income....More>>>
” Even as I approach the gambling hall, as soon as I hear, two rooms away, the jingle of money poured out on the table, I almost go into convulsions.” /Fyodor Dostoevsky
The newly legislated entry into the global gaming market by Japan has raised prospects of a $30 billion market forming within the first five years of operation. As the implications of this game changing development....More>>>
It’s been a long decade for Yahoo (Nasdaq: YHOO). The search and tech company has seen its stock rise just 10% over the past 10 years.
This comes after years of battling activist investors, a carousel of CEOs, and a declining business. The saving grace has been Alibaba (Nasdaq: BABA), where Yahoo has a 15% stake in the company. The success of Alibaba has helped overshadow Yahoo’s....More>>>
Luxoft Holding (LXFT) saw a huge downward move after reporting earnings on August 11th. We think the market overreacted to the temporary drop in profitability, forgetting about the future growth potential and the efforts underway to grow some of its verticals such as healthcare dramatically in th
Therapix Biosciences (NASDAQ:TRPX) received an initiation of coverage from Laidlaw & Company analyst Francois Brisebois who gave the company a Buy rating and a $18.00 price target. Therapix's lead drug is an FDA approved dronabinol, which is a biosynthetic form of THC. The company's stra
Why should investors like marijuana stocks? For some, the rationale might be the enormous market potential. For others, it could be simply that many marijuana stocks have soared over the last year or so.
There are plenty of reasons for investors to like three marijuana stocks in parti